Literature DB >> 2906153

Neuroendocrine evidence for serotonin receptor hypersensitivity in panic disorder.

R S Kahn1, G M Asnis, S Wetzler, H M van Praag.   

Abstract

Normal controls (NC) (n = 15), patients with panic disorder (PD) (n = 13) and patients with major depression (MD) (n = 17) were challenged with a single, oral dose (0.25 mg/kg) of the selective 5HT agonist m-chlorophenyl-piperazine (MCPP) or placebo. Blood samples were assayed for cortisol and MCPP levels every 30 min. The PD group had an augmented cortisol release when compared to the other two groups. Finally, a significant correlation was found across all subjects between clinical anxiety level and cortisol release on MCPP. These data support the hypothesis of 5HT receptor hypersensitivity in PD.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2906153     DOI: 10.1007/BF00216062

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  23 in total

Review 1.  Serotonin and anxiety revisited.

Authors:  R S Kahn; H M van Praag; S Wetzler; G M Asnis; G Barr
Journal:  Biol Psychiatry       Date:  1988-01-15       Impact factor: 13.382

2.  Disposition and pharmacological effects of m-Chlorophenylpiperazine in rats.

Authors:  R W Fuller; H D Snoddy; N R Mason; J E Owen
Journal:  Neuropharmacology       Date:  1981-02       Impact factor: 5.250

3.  Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects.

Authors:  D S Charney; S W Woods; W K Goodman; G R Heninger
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

Review 4.  Increased anxiogenic effects of caffeine in panic disorders.

Authors:  D S Charney; G R Heninger; P I Jatlow
Journal:  Arch Gen Psychiatry       Date:  1985-03

5.  Further studies of the putative serotonin agonist, m-chlorophenylpiperazine: evidence for a serotonin receptor mediated mechanism of action in humans.

Authors:  E A Mueller; D L Murphy; T Sunderland
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

6.  Influence of yohimbine on release of anterior pituitary hormones.

Authors:  M R Goldberg; R V Jackson; J Krakau; D P Island; D Robertson
Journal:  Life Sci       Date:  1986-08-04       Impact factor: 5.037

7.  Neuroendocrine effects of M-chlorophenylpiperazine, a serotonin agonist, in humans.

Authors:  E A Mueller; D L Murphy; T Sunderland
Journal:  J Clin Endocrinol Metab       Date:  1985-12       Impact factor: 5.958

8.  Neuroendocrine correlates of lactate-induced anxiety and their response to chronic alprazolam therapy.

Authors:  D B Carr; D V Sheehan; O S Surman; J H Coleman; D J Greenblatt; G R Heninger; K J Jones; P H Levine; W D Watkins
Journal:  Am J Psychiatry       Date:  1986-04       Impact factor: 18.112

9.  Research diagnostic criteria: rationale and reliability.

Authors:  R L Spitzer; J Endicott; E Robins
Journal:  Arch Gen Psychiatry       Date:  1978-06

10.  L-5-hydroxytryptophan in the treatment of anxiety disorders.

Authors:  R S Kahn; H G Westenberg
Journal:  J Affect Disord       Date:  1985 Mar-Apr       Impact factor: 4.839

View more
  19 in total

Review 1.  The 5-HT receptor--G-protein--effector system complex in depression. I. Effect of glucocorticoids.

Authors:  K P Lesch; B Lerer
Journal:  J Neural Transm Gen Sect       Date:  1991

2.  Effects of the 5-HT1A receptor agonist flesinoxan in panic disorder.

Authors:  I M van Vliet; H G Westenberg; J A den Boer
Journal:  Psychopharmacology (Berl)       Date:  1996-09       Impact factor: 4.530

3.  Association Study between 5-HT1A Receptor Gene C(-1019)G Polymorphism and Panic Disorder in a Korean Population.

Authors:  Won-Seok Choi; Bun-Hee Lee; Jong-Chul Yang; Yong-Ku Kim
Journal:  Psychiatry Investig       Date:  2010-04-06       Impact factor: 2.505

4.  Experimental studies on 3,4-methylenedioxymethamphetamine (MDA, "ecstasy") and its potential to damage brain serotonin neurons.

Authors:  G A Ricaurte; U D McCann
Journal:  Neurotox Res       Date:  2001-01       Impact factor: 3.911

Review 5.  [Experimental provocation of panic attacks as a human experimental model for anxiety].

Authors:  A Ströhle
Journal:  Nervenarzt       Date:  2003-09       Impact factor: 1.214

Review 6.  Exploring exercise as an avenue for the treatment of anxiety disorders.

Authors:  Lindsey B DeBoer; Mark B Powers; Angela C Utschig; Michael W Otto; Jasper A J Smits
Journal:  Expert Rev Neurother       Date:  2012-08       Impact factor: 4.618

7.  A dose-response study of intravenous m-chlorophenylpiperazine in normal subjects.

Authors:  O Kalus; S Wetzler; R S Kahn; G M Asnis; H M van Praag
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

8.  Pentagastrin induced panic attacks: enhanced sensitivity in panic disorder patients.

Authors:  H J van Megen; H G Westenberg; J A den Boer; J R Haigh; M Traub
Journal:  Psychopharmacology (Berl)       Date:  1994-04       Impact factor: 4.530

9.  Modelling anxiety in humans for drug development.

Authors:  Martin Siepmann; Peter Joraschky
Journal:  Curr Neuropharmacol       Date:  2007-03       Impact factor: 7.363

10.  5-HT1A receptor-effector system responsivity in panic disorder.

Authors:  K P Lesch; M Wiesmann; A Hoh; T Müller; J Disselkamp-Tietze; M Osterheider; H M Schulte
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.